Compliance with the measures for preventing vascular risk factors in hospitalised patients with acute stroke. Analysis of a national multi-centre registry: Epices registry (III);Cumplimiento de las medidas de prevención de factores de riesgo vascular en pacientes ingresados con ictus agudo. análisis de un registro multicéntrico: Registro epices (III)

Revista de Neurologia

Volumn 54, Issue 9, 2012, Pages 523-529

  Blanco, Miguel ^a   Vivancos Mora, José ^b   Castillo, José ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Cerebrovascular disease; Primary prevention; Risk factors; Secondary prevention

Indexed keywords

AGE; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; HOSPITAL PATIENT; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; NEUROLOGIST; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; SECONDARY PREVENTION; SENESCENCE; TRANSIENT ISCHEMIC ATTACK;

EID: 84862064454     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5409.2012213     Document Type: Article

References (26)

1. Goldstein LB, Busnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517-584.
2. Fuentes B, Gállego J, Gil-Núñez A, Morales A, Purroy F, Roquer J, et al. Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida. Neurologia 2011; Sep 3 [Epub ahead of print].
3. Clua-Espuny JL, Piñol-Moreso JL, Gil-Guillén VF, Orozco-Beltrán D, Panisello-Tafalla A, Lucas-Noll J, et al. Resultados de prevención cardiovascular primaria y secundaria en pacientes con ictus: riesgo de recurrencia y supervivencia asociada (estudio Ebrictus). Rev Neurol 2012; 54: 81-92.
4. Brotons C, Soriano N, Moral I, Rodrigo MP, Kloppe P, Rodríguez AI, et al. Randomized clinical trial to assess the efcacy of a comprehensive programme of secondary prevention of cardiovascular disease in general practice: the PREseAP study. Rev Esp Cardiol 2011; 64: 13-20.
5. Lawrence M, Kerr S, Watson H, Paton G, Ellis G. An exploration of lifestyle beliefs and lifestyle behaviour following stroke: fndings from a focus group study of patients and family members. BCM Fam Pract 2010; 11: 97.
6. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
7. Chen CXR, Chan SL, Law TC, Choi SK, Chan KH. Secondary prevention of stroke: an evidence-based clinical audit in the primary care. Hong Kong Med J 2011; 17: 469-477.
8. Lee S, Shafe ACE, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open 2011; 2: e000269.
9. Vaarjes I, Van Dis I, Grobbee DE, Bots ML. Te dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke. BCM Cardiovasc Disord 2010; 10: 57.
10. Da Luz PL, Nishiyama M, Chagas ACP. Drugs and lifestyle for the treatment and prevention of coronary artery disease -comparative analysis of the scientifc basis. Braz J Med Biol Res 2011; 44: 973-991.
11. Ford ES, Ajani VA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in US death from coronary disease, 1980-2000. N Eng J Med 2007; 356: 2388-2398.
12. Orbiagele B, Saver J, Fredier A, Suzuki S, McNair N, Dandekar R, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004; 63: 1217-1222.
13. Hippisley-Cox J, Coupland C. Efect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005; 330: 1059-1063.
14. Fuster V, Sanz G. Compuestos de dosis fja en la prevención secundaria de la cardiopatía isquémica. Rev Esp Cardiol 2011; 64 (Supl 2): S3-S9.
15. Stroke Association. 'Nobody told me...'. Highlighting the importance of information for stroke survivors when they leave hospital. London: Stroke Association; 2005.
16. Lawrence M, Kerr S, Watson H, Jackson J, Brownlee M. A summary of the guidance relating to four lifestyle risk factors for recurrent stroke: tobacco use, alcohol consumption, diet and physical activity. Br J Neurosci Nurs 2009; 5: 471-476.
17. Park EW, Schult JK, Tudiver F, Campbell T, Becker L. Enhancing partner support to improve smoking cessation. Cochrane Database Syst Rev 2004; 3: CD002928.
18. Arias-Rivas S, Vivancos-Mora J, Castillo J, en nombre de los investigadores del registro EPICES. Epidemiología de los subtipos de ictus en pacientes hospitalizados atendidos por neurólogos: resultados del registro EPICES (I). Rev Neurol 2012; 54: 385-393.
19. Castillo J, Vivancos-Mora J, en nombre de los investigadores del registro EPICES. Tiempos de llegada al hospital y hasta la atención neurológica de pacientes con ictus agudo. Análisis de un registro multicéntrico nacional: registro EPICES (II). Rev Neurol 2012; 54: 461-467.
20. Zimetbaum PJ, Tesami A, Yu HT, Xiong Y, Liu J, Kothawala P, et al. Are atrial fbrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010; 123: 446-453.
21. Abellán-Alemani J, Ruilope-Urioste LM, Leal-Hernández M, Armario-García P, Tiberio-López G, Martell-Claros N. Control de los factores de riesgo cardiovasculares en pacientes con ictus atendidos en atención primaria en España. Estudio ICTUSCARE. Med Clin (Barc) 2011; 136: 329-335.
22. Vidal-Pérez R, Otero-Raviña F, Domínguez-López J, Fabeiro-Romero D, Gómez-Vázquez JL, De Blas-Abad P, et al, En representación de los investigadores del Grupo Barbanza. Características clínicas y pronóstico de pacientes con enfermedad cerebrovascular crónica (estudio ICBAR). Rev Neurol 2011; 53: 449-456.
23. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Te task force on diabetes and cardiovascular diseases of the European Society of Cardiology and of the European Association for the Study of Diabetes. Eur Heart J 2007; 28: 88-136.
24. Tufano A, Cimino E, Di Minno MND, Ierano P, Marrone E, Strazzullo A, et al. Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs. Int J Vas Med 2011; 2011: 250518.
25. De Velasco JA, Cosin J, López-Sendón JL, De Teresa E, De Oya M, Sellers G. New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study. Rev Esp Cardiol 2002; 55: 801-809.
26. Gil-Núñez A, Vivancos J, Gabriel R. Diagnóstico y prevención secundaria del infarto cerebral en España. Estudio DIAPRESIC. Med Clin (Barc) 2008: 131: 765-769.